From: LC-MSMS based screening of emerging pollutant degradation by different peroxidases
 | Category | Emerging pollutant | Structure | Retention Time (min) | MRM Transition (m/z) | Dwell time (ms) | Frag-mentor Voltage (V) | Collision Energy (V) | Polarity |
---|---|---|---|---|---|---|---|---|---|
1 | Antibiotic | Roxithromycin | 11.6 | 837 âž” 680 | 200 | 135 | 20 | Positive | |
2 | Lincomycin-HCl | 7.6 | 407 âž” 359 | 200 | 135 | 20 | Positive | ||
3 | Norfloxacin | 8.2 | 320 âž” 302 | 200 | 135 | 20 | Positive | ||
4 | Trimethoprim | 7.9 | 291 âž” 230 | 200 | 135 | 20 | Positive | ||
5 | Sulfamethoxazole | 9.3 | 254 âž” 156 | 200 | 135 | 20 | Positive | ||
6 | Antidepressant | Venlafaxine-HCl | 9.4 | 278 âž” 260 | 200 | 135 | 10 | Positive | |
7 | Antioxidant | Caffeic acid | 7.8 | 181 âž” 163 | 200 | 135 | 20 | Positive | |
8 | Anti-seizure drug | Phenytoin | 11.1 | 253 âž” 182 | 200 | 135 | 10 | Positive | |
9 | Diuretic drug | Hydrochloro-thiazide | 6.4 | 296 âž” 269 | 70 | 140 | 20 | Negative | |
10 | Furosemide | 11 | 329 âž” 285 | 70 | 140 | 15 | Negative | ||
11 | Beta-blocker (high blood pressure drug) | Atenolol | 7.1 | 267 âž” 190 | 200 | 135 | 20 | Positive | |
12 | Fungicide | Thiabendazole | 7.6 | 202 ➔175 | 200 | 135 | 30 | Positive | |
13 | Herbicide | Prometryn | 11.6 | 242 âž” 158 | 200 | 135 | 30 | Positive | |
14 | MCPA | 12 | 201 âž” 125 | 200 | 47 | 13 | Positive | ||
15 | Fluometuron | 11.7 | 233 âž” 72 | 200 | 135 | 30 | Positive | ||
16 | Histamine H2 receptor antagonist | Cimetidine | 6.9 | 253 âž” 159 | 200 | 135 | 10 | Positive | |
17 | Insect repellent | DEET | 11.9 | 192 âž” 119 | 200 | 135 | 30 | Positive | |
18 | Nonsteroidal anti-inflammatory drug (NSAID) | Meloxicam | 12.8 | 352 âž” 115 | 200 | 135 | 6 | Positive | |
19 | Ibuprofen | 14.4 | 207 âž” 161 | 200 | 135 | 20 | Positive | ||
20 | Stimulant | Caffeine | 7.8 | 195 âž” 138 | 200 | 135 | 30 | Positive | |
21 | Vulcanization agent (for rubber) | 2-Mercapto Benzothiazole (MBT) | 10.6 | 168 âž” 135 | 200 | 135 | 30 | Positive |